21: What type of a name is Nantkwest anyway?

Armchair Healthcare

English - November 19, 2018 07:00 - 41 minutes - 45.7 MB - ★★★★★ - 11 ratings
Investing Business Science healthcare pharmaceuticals biotech biotechnology stock market drugs placebo science shorting stocks finance Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: 20: Interview with Jonathan Tepper, author of The Myth of Capitalism

Next Episode: 22: CRISPR baby one more time

If two drugs are better than one, six must be frickin' amazing. Also, Max and Nat figure out hot to improve NASH data and the tax system. Here's a little table of contents:

00:54 Nantkwest sextuplet cancer therapy

05:00 NWBO's horrible financing

09:15 AMZN and FB make some waves

19:39 Moderna's IPO

22:45 Are Alzheimer's drugs doomed?

25:30 MDGL and NASH

30:57 The Healthcare Cost Institute shows that NP's and PA's are no cheaper than MD's.

36:13 Should drug prices be disclosed in ads?